ArriVent Biopharma Inc., a clinical-stage biopharmaceutical company, has announced the pricing of a $75 million public offering of common stock and pre-funded warrants. The company has filed an automatic shelf registration statement on Form S-3ASR with the SEC, which became effective upon filing on February 3, 2025. The offering includes 2,482,692 shares of common stock priced at $19.50 each and pre-funded warrants for an additional 1,363,469 shares. The proceeds are intended to support the company's pipeline programs and general corporate purposes. The offering, expected to close around July 3, 2025, is managed by Goldman Sachs, Citigroup, and Guggenheim Securities, among others.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.